Therefore, the blockade of CD95L might be a significant approach to overcome the problem of chemo-resistance by diminishing the potential pro-inflammatory crosstalk role of TNF-α and TRAIL in the treatment of inflammation-driven tumor progression of PDAC. The gene discussed is FASLG; the disease is neoplasm.